Nitazene derivative DFNZ delivers potent analgesia without respiratory depression or addiction signals in preclinical models
A compound derived from the notorious nitazene class of synthetic opioids has demonstrated powerful analgesic properties in rodent models whilst avoiding the cardinal adverse effects – respiratory depression, tolerance, dependence, and addiction – that have long been considered inseparable from high-efficacy muopioid receptor agonism. The findings, published in Nature, may fundamentally alter the pharmacological framework guiding the development of safer opioid analgesics.
Researchers at the National Institutes of Health (NIH), Stanford University, Boston University, and several collaborating institutions have identified N-desethyl-fluornitrazene (DFNZ), a metabolite of the synthetic benzimidazole opioid fluornitrazene (FNZ), as a µ-opioid receptor (MOR) superagonist with a safety profile that challenges prevailing assumptions in opioid pharmacology.
“Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose,” said Nora D. Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA). “Developing a highly effective pain medication without these drawbacks would have enormous public health benefits.”
From a forgotten compound class to a novel candidate
Nitazenes – a class of 2-benzylbenzimidazole synthetic opioids first synthesised in the 1950s – were abandoned clinically because of extreme potency and overdose risk. Several analogues have since appeared in the illicit drug supply and been scheduled by the US Drug Enforcement Administration following overdose fatalities. The current investigators took a different approach: rather than avoid the class entirely, they sought to exploit its high MOR selectivity whilst engineering a safer pharmacological profile.
The team first characterised FNZ itself, confirming high MOR affinity (inhibition constant Ki = 1.36 ± 0.11 nM) and supramaximal intrinsic efficacy – exceeding DAMGO as the reference agonist – at Gi1, GoA, β-arrestin 1, and β-arrestin 2 signalling pathways. Using ¹⁸F-radiolabelled FNZ in positron emission tomography (PET) studies, they found rapid brain entry and washout within ten minutes. Despite this transient cerebral exposure, analgesia in rats persisted for at least two hours, prompting investigation of active metabolites.
Metabolite identification via high-performance liquid chromatography–mass spectrometry confirmed that DFNZ, produced by N-dealkylation, accounted for more than 50% of FNZ metabolism in mouse liver microsomes. DFNZ retained equivalent MOR selectivity and affinity (Ki = 1.00 ± 0.06 nM) but showed a divergent spatiotemporal signalling profile.
Impaired brain penetrance as a mechanism of safety
A critical pharmacokinetic finding was that DFNZ is a substrate of both P-glycoprotein (PGP) and breast cancer resistance protein (BCRP) – the principal efflux transporters at the blood–brain barrier. Brain-to-plasma ratio studies demonstrated values of 0.9–1.5 for DFNZ versus 2.4–3.2 for FNZ in rats, consistent with restricted cerebral accumulation. In PGP/BCRP-knockout mice, [³H]DFNZ showed widespread brain accumulation, confirming in vivo efflux. At therapeutic doses in rats, DFNZ produced MOR occupancy in the nucleus accumbens (NAc) comparable to that of doses of FNZ 60- to 200-fold lower, despite requiring 60-fold higher doses to achieve equivalent analgesia.
This impaired brain penetrance appears to underlie DFNZ’s respiratory safety. Electrochemical oxygen measurements in freely moving rats demonstrated that intravenous DFNZ at doses producing maximal subcutaneous analgesia did not cause NAc hypoxia – in stark contrast to equianalgesic doses of fentanyl and FNZ. When the PGP inhibitor tariquidar was co-administered, DFNZ produced significant cerebral hypoxia, confirming that the safe respiratory profile is directly attributable to PGP-mediated efflux.
Subcutaneous DFNZ at the maximal analgesic dose (1 mg kg⁻¹) produced a sustained, moderate increase in brain oxygen levels lasting at least 60 minutes – an unexpected and potentially beneficial finding.
Tolerance, withdrawal, and addiction liability
Repeated daily dosing at doses threefold above the analgesic ED₅₀ over seven days produced naloxone-precipitated withdrawal scores approximately 70% lower than morphine. Of 14 standard withdrawal criteria, DFNZ triggered only irritability/vocalisation. Escalating doses over one month produced neither mechanical hypersensitivity, tolerance, nor the NAc MOR density reduction characteristic of fentanyl exposure.
In intravenous self-administration studies – the standard preclinical model for predicting human abuse liability – rats readily acquired DFNZ self-administration, confirming reinforcing properties. However, when DFNZ was replaced with saline during extinction sessions, lever-pressing ceased almost immediately, a pattern resembling ketamine rather than heroin or morphine.
Fibre photometry using the genetically encoded dopamine sensor dLight1.3b revealed that DFNZ promoted slow tonic dopamine release in the NAc without inducing the fast phasic dopamine transients associated with reinforcement learning and cue-conditioned craving. This dissociation appears mechanistically linked to DFNZ’s markedly reduced efficacy at MOR–galanin 1 receptor (GAL1) heteromers in the ventral tegmental area, confirmed using NanoBiT assays and selective heteromer-disrupting peptides in microdialysis experiments.
Implications for pain medicine and opioid use disorder
“DFNZ has an unprecedented pharmacology for an opioid,” said Michael Michaelides, Ph.D., senior author and NIDA investigator. “It is a potent and high-efficacy analgesic, but in certain contexts it resembles partial agonists, drugs that activate the receptor with low efficacy, which is what scientists think is needed for safety. Its capacity to be administered at therapeutic doses without producing respiratory depression is very important.”
As the authors note in the paper’s conclusion: “Our findings challenge the conventional dogma that high-efficacy MOR agonists are unsuitable for development as safe analgesics… Additionally, given the favourable safety profile of DFNZ and its ability to reduce heroin self-administration, sustained-release formulations of DFNZ should be explored as novel opioid maintenance treatments.”
Study limitations acknowledged by the authors include insufficient subject numbers to evaluate sex-dependent differences in some behavioural assays, and the absence of pain-state models of self-administration. The team has indicated plans to continue preclinical work towards regulatory approval for human studies.
Journal reference: Gomez, J. L., Ventriglia, E. N., Frangos, Z. J., et al. (2026). A µ-opioid receptor superagonist analgesic with minimal adverse effects. Nature.
https://doi.org/10.1038/s41586-026-10299-9
